REGENXBIO-Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

Regenxbio (RGNX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of$ 1.29. This compares to loss of $1.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 18.60%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 1.28 per share when it actually produced a loss of $1.38, delivering a surprise of -7.81%. Over the last four quarters, the company ha ...